Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $60.38, for a total value of $1,509,500.00. Following the completion of the sale, the chief executive officer directly owned 1,048,095 shares in the company, valued at $63,283,976.10. This represents a 2.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Thursday, May 21st, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $61.13, for a total value of $1,528,250.00.
• On Tuesday, May 19th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $58.65, for a total value of $1,466,250.00.
• On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $57.04, for a total value of $1,426,000.00.
• On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $56.29, for a total value of $1,407,250.00.
• On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $41.50, for a total value of $1,037,500.00.
• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total value of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The stock was sold at an average price of $40.00, for a total value of $132,000.00.

Liquidia Stock Down 1.4%

LQDA opened at $60.10 on Wednesday. Liquidia Corporation has a one year low of $11.85 and a one year high of $62.30. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The stock’s fifty day moving average is $43.00 and its 200-day moving average is $37.80. The company has a market capitalization of $5.34 billion, a PE ratio of 429.32 and a beta of 0.41.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, equities analysts predict that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Federated Hermes Inc. purchased a new position in shares of Liquidia during the third quarter valued at $7,290,000. Caprock Group LLC purchased a new position in shares of Liquidia during the third quarter valued at $37,114,000. Apis Capital Advisors LLC purchased a new position in shares of Liquidia during the third quarter valued at $9,569,000. Farallon Capital Management LLC grew its holdings in shares of Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares in the last quarter. Finally, GSA Capital Partners LLP grew its holdings in shares of Liquidia by 63.6% during the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after buying an additional 24,555 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LQDA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. BTIG Research boosted their target price on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Oppenheimer boosted their target price on Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research report on Thursday, March 12th. Finally, Wells Fargo & Company boosted their target price on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).